A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
LigaChem Biosciences, Inc.
Dana-Farber Cancer Institute
Intensity Therapeutics, Inc.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Novartis
Novartis